Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

Only three months after banking an eye-popping $350 million series D round, Eikon Therapeutics is blaming government funding ...

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

French biotech OSE Immunotherapeutics is taking charge of a new project aimed at fast-tracking nanodrug development and ...

When mice implanted with metastasis-prone human cancer cells were treated with compounds that targeted ACBP’s activity, none ...

Having already worked with clinical trial sites in more than 14 states, CTAC will now take its work nationwide, the ...

A Hong Kong-based developer of a catalog of urine-based tests for cancer, infectious diseases, women’s health and more has ...

Medtronic plans to separate from its diabetes business and launch it as an independent company—one that will count more than ...

Despite Merck KGaA’s lupus drug failing to prove itself against one form of the autoimmune disease, the German drugmaker has ...

Moderna filed for FDA approval of its mRNA-1083 combination shot last year. The submission put the biotech on track to win ...

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

Roivant has its own TYK2/JAK1 inhibitor in development in the form of brepocitinib, which the biopharma licensed from Pfizer ...